Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.…
Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization
Rezolute (NASDAQ: RZLT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 63 employees.
The shares were at 3.920 USD on 20 November 2026, down 59.2% over 52 weeks. Its 52-week range is 1.070 USD to 11.46 USD: the price is 65.8% below the high and 266.4% above the low.
Its market capitalisation is 465.58M USD.
Rezolute reports return on equity of -77.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 89.25M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 10.80 USD is 175.5% above the current price. The next earnings report is expected on 11 February 2027.